FTO inhibitors (e.g., CS1, FB23-2) appreciably impair the growth of resistant cells either alone or in combination with nilotinib...These findings offer new insights into cancer drug resistance and advance the application of RNA nanotechnology for treating leukemia. The research provides a foundation for developing novel, targeted therapies for resistant leukemia.

P2, N=45, Not yet recruiting, University Health Network, Toronto

P=N/A, N=600, Recruiting, Novartis Pharmaceuticals | N=100 --> 600 | Trial completion date: Jul 2025 --> Jun 2030 | Trial primary completion date: Jul 2025 --> Jun 2030

Overall, this work applies bioisosteric replacement to generate a new chemotype and uncovers a mechanistically divergent lead. The distinct, ABL1-independent mechanism of compound 2a establishes a solid foundation for future optimization and highlights its potential as a starting point for developing novel antimyeloproliferative agents with a different therapeutic profile.

The initial treatment approach emphasized cytoreduction therapy with hydroxyurea, intravenous fluid administration, and preventive medication with allopurinol to protect against the risk of tumor lysis syndrome. After the patient became stabilized, imatinib, a first-line tyrosine kinase inhibitor, was started...As highlighted by this case, the importance of prompt diagnosis, the initiation of cytoreduction therapy, and the use of molecular therapy in treating CML in children cannot be neglected. CML in children is an uncommon but curable form of leukemia.

Surgical resection is the standard treatment for localized GIST. Imatinib is the first-line prescribed treatment, with particular attention to potentially life-threatening adverse effects.

Postoperatively, the patient received only 1 year of adjuvant imatinib (400 mg/day) and remained disease-free for the subsequent 14 years, until liver lesions were incidentally identified during a routine physical examination...This case is clinically distinctive owing to its ultra-long recurrence interval and synchronous bifocal hepatic metastasis, thereby offering valuable insights into the long-term natural course of GISTs in the setting of inadequate adjuvant tyrosine kinase inhibitor (TKI) therapy. Furthermore, it underscores the necessity of long-term postoperative surveillance for patients with GIST and highlights the potential role of comprehensive genetic testing in guiding individualized treatment decisions.

P4, N=85, Completed, Novartis Pharmaceuticals | Active, not recruiting --> Completed | Trial completion date: Nov 2026 --> Mar 2026 | Trial primary completion date: Nov 2026 --> Mar 2026

P3, N=135, Not yet recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University

P1, N=36, Completed, Centre for Human Drug Research | Suspended --> Completed

P=N/A, N=600, Recruiting, Pfizer | Active, not recruiting --> Recruiting

Neoadjuvant imatinib in locally advanced DFSP results in tumor volume reduction without decreasing the final surgical defect. The histological response is typically patchy and may compromise detection of residual disease, potentially increasing the risk of local recurrence.